U.S. stock indices slump amid tariff talks while healthcare sees major developments: J&J faces a $1.6B lawsuit, new FDA approvals, and a $2B ...

Stock analysts at Zacks Research upped their FY2027 earnings per share estimates for GSK in a report issued on Tuesday, March ...

GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on SSTK. Our Pro platform offers fair value estimates, performance predictions, and risk ...

Our congratulations go to the 10 charities that have won 2025 GSK IMPACT Awards for their outstanding contributions to improving the UK’s health and wellbeing. The following organisations will receive ...

This comprehensive analysis examines CAVA’s recent financial performance, growth strategies, and the challenges it faces in maintaining its momentum. According to InvestingPro data, CAVA has ...

Find out more at gsk.com The King's Fund is an independent charity working to improve health and care in England. We help to shape policy and practice through research and analysis; develop ...

DUBLIN--(BUSINESS WIRE)--The "Enterprise Tech Ecosystem Series: GSK plc 2024" company profile has been added to ResearchAndMarkets.com's offering. The report provides insights into company's tech ...

The "Enterprise Tech Ecosystem Series: GSK plc 2024" company profile has been added to ResearchAndMarkets.com's offering.

GSK Pushes First-in-Class Antibiotic for Uncomplicated UTI By March 26, the FDA is scheduled to release its verdict on GSK’s investigational antibiotic gepotidacin for the treatment of uncomplicated ...